Special Drug Use Investigation for AMERGE® Tablet (Long-term)

Special Drug Use Investigation for AMERGE Tablet (Long-term)

To investigate the long-term safety and efficacy of AMERGE (naratriptan hydrochloride) on Japanese patients with migraine headache in clinical setting

Inclusion Criteria:

• Must use AMERGE for the first time

Exclusion Criteria:

• Patients with hypersensitivity to naratriptan or any of the components.
• Patients with history, symptoms, or signs of myocardial infarction, ischemic cardiac or angina inversa
• Patients with history of cerebral vascular disturbance or transient ischaemic attack
• Patients with peripheral vascular syndromes
• Patients with uncontrolled hypertension
• Patients with severe renal or hepatic impairment
• Patients using treatment with another 5-HT1 agonist, an ergotamine-containing or ergot-type medication